Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$88.82 USD
+0.53 (0.60%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $88.74 -0.08 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.82 USD
+0.53 (0.60%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $88.74 -0.08 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy
by Zacks Equity Research
Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.
Gilead Down on Mixed Results From Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.
Regeneron Expands Deal With Intellia for Hemophilia Treatments
by Zacks Equity Research
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Markets Neutral to Kick Off New Week & Month
by Mark Vickery
Increased levels of stress both at home and abroad aren't exactly being shrugged off by the market, but they're not being particularly negatively affected either.
Market Awaits Major Economic Data This Week
by Zacks Equity Research
Market Awaits Major Economic Data This Week
Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners
by Ritujay Ghosh
Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.
Merck (MRK) Shares Looking Ripe For A Buy
by Daniel Laboe
Merck (MRK) is a pharmaceutical powerhouse that has been under-appreciated amid this health crisis
Why Is Gilead (GILD) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche Starts Study on Actemra with Gilead's Drug for Coronavirus
by Zacks Equity Research
Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs
by Zacks Equity Research
Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
3 Top-Ranked Stocks With Upgraded Broker Ratings to Buy Now
by Swayta Shah
It is advisable to follow broker ratings to find attractive stocks, given the uncertain operating backdrop.
Intercept Down on Postponement of AdCom Meet for NASH Drug
by Zacks.com
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Regeneron (REGN) to Buy Back Part of Its Stake Held by Sanofi
by Zacks Equity Research
Regeneron (REGN) commences underwritten public secondary offering of its common stock held by Sanofi and repurchases shares for $5 billion.
Pre-Markets Race Higher on Vaccine Hopes
by Mark Vickery
Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
by Kinjel Shah
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development
by Zacks Equity Research
Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.
Can Teva (TEVA) Return to Growth in This Year or Next?
by Zacks Equity Research
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
Gilead, Galapagos Announce Positive Data on Inflammatory Drug
by Zacks Equity Research
Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.